Polycyclo Ring System Having The Hetero Ring As One Of The Cyclos Patents (Class 514/468)
-
Publication number: 20140080796Abstract: The present invention relates to the use of a compound of Formula I for the manufacture of a medicament for treating or preventing cancer in a subject.Type: ApplicationFiled: February 13, 2012Publication date: March 20, 2014Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Kathy Qian Luo, Ting Yu, Hou-Wei Luo
-
Publication number: 20140073592Abstract: Codling moth, Cydia pomonella, (L.), is a cosmopolitan pest of the apple, potentially causing damage to circa 80% of the fruit. Disclosed here are use of extract of Ginkgo biloba, or its synthetic metabolites for preventing or treating apple feeding and infestation by neonate larvae of codling moth.Type: ApplicationFiled: September 11, 2013Publication date: March 13, 2014Applicant: Missouri State UniversityInventors: Maciej A. Pszczolkowski, Kevin Durden, Samantha Sellars, Brian Cowell, John J. Brown
-
Publication number: 20140066499Abstract: An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture.Type: ApplicationFiled: November 13, 2013Publication date: March 6, 2014Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinichi Urayama, Eigo Mutou, Atsushi Inagaki, Takashi Okada, Shigeharu Sugisaki
-
Patent number: 8664266Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.Type: GrantFiled: April 30, 2013Date of Patent: March 4, 2014Assignee: Fred Hutchinson Cancer Research CenterInventors: Valeri I. Vasioukhin, John R. Chevillet
-
Publication number: 20140057976Abstract: Topical skin treatment formulation containing usnic acid or an usnate salt, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of microbial conditions, in particular acne. The solvent system assists in the effective dissolution of the usnic acid or usnate and in targeting its delivery to relevant sites on the skin.Type: ApplicationFiled: March 26, 2012Publication date: February 27, 2014Applicant: EVOCUTIS PLCInventors: Steven John Abbott, Gavin Donoghue, Elizabeth Anne Eady
-
Publication number: 20140047569Abstract: The present invention relates to methods of treatment of clinical disorders associated with protein aggregation comprising administering, to a subject, an effective amount of an anti-protein aggregate (“APA”) compound selected from the group consisting of pimozide, fluphenazine (e.g., fluphenazine hydrochloride), tamoxifen (e.g., tamoxifen citrate), taxol, cantharidin, cantharidic acid, salts thereof and their structurally related compounds. It is based, at least in part, on the discovery that each of the aforelisted compounds were able to promote degradation of aggregated ATZ protein in a Caenorhabditis elegans model system. According to the invention, treatment with one or more of these APA compounds may be used to ameliorate the symptoms and signs of AT deficiency as well as other disorders marked by protein aggregation, including, but not limited to, Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.Type: ApplicationFiled: May 3, 2012Publication date: February 13, 2014Applicant: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Stephen C. Pak, David Hirsch Perlmutter, Gary A. Silverman
-
Patent number: 8642648Abstract: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.Type: GrantFiled: October 9, 2012Date of Patent: February 4, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yutaka Tanoue, Tetsuya Matsuura, Yutaka Yamagata, Naoki Nagahara
-
Patent number: 8642649Abstract: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.Type: GrantFiled: October 9, 2012Date of Patent: February 4, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Yutaka Tanoue, Tetsuya Matsuura, Yutaka Yamagata, Naoki Nagahara
-
Patent number: 8629178Abstract: The present invention relates to sodium tanshinone IIA sulfonate hydrates as well as preparation methods and uses thereof. The sodium tanshinone IIA sulfonate hydrates have molecular formla of C19H17NaO6S.nH2O, wherein n=0.5-4.0. The sodium tanshinone IIA sulfonate hydrates of the present invention have better storage stability than anhydrous sodium tanshinone IIA sulfonate.Type: GrantFiled: November 3, 2010Date of Patent: January 14, 2014Inventor: Li Liu
-
Publication number: 20140011761Abstract: Endoplasmic reticulum stress has been found to be associated with the genetic disease tuberous sclerosis. Tuberous sclerosis is cause by defects in the two genes, TSC1 and TSC2. Agents that modulate ER stress may be used to treat tuberous sclerosis and other hamartomatous diseases. In particular, 4-phenyl butyric acid (PBA) has been shown to reduce ER stress is TSC-deficient cells. Other compounds useful in reducing ER stress are chemical chaperones such as trimethylamine N-oxide arid glycerol may also be useful in treating tuberous sclerosis. The present invention provides methods of treating a subject suffering from tuberous sclerosis using ER stress reducers such as PBA, TUDCA, UDCA, and TMAO. Methods of screening for ER stress reducers by identifying agents that reduce levels of ER stress markers in TSC-deficient cells are also provided. These agents may find use in methods and pharmaceutical compositions for treating tuberous sclerosis.Type: ApplicationFiled: December 20, 2012Publication date: January 9, 2014Applicant: President and Fellows of Harvard CollegeInventors: Gokhan S. Hotamisligil, Umut Ozcan, Brendan D. Manning
-
Publication number: 20140005250Abstract: A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.Type: ApplicationFiled: November 7, 2011Publication date: January 2, 2014Applicant: THE OHIO STATE UNIVERSITYInventors: John C. Byrd, Amy J. Johnson, Emilia Mahoney, David M. Lucas, Michael R. Grever
-
Publication number: 20130345176Abstract: The present invention discloses esters of 4,9-dihydroxy-naphtho[2,3-b]furans and methods of making and using the same. The present invention also discloses conversion of the esters into therapeutically active 4,9-dihydroxy-naphtho[2,3-b]furans in vivo. The present invention furthermore discloses pharmaceutical compositions comprising the esters of 4,9-dihydroxy-naphtho[2,3-b]furans for the treatment of various indications including proliferative diseases.Type: ApplicationFiled: March 4, 2011Publication date: December 26, 2013Applicant: Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd.Inventors: Zhiwei Jiang, Aijin Wang, Hongwei Hu, Jiali Xu, Yuesong Hu, Xian Li, Yan Ye, Jie Wang, Qinglong Li
-
Publication number: 20130344183Abstract: The present invention relates to a novel compound isolated from Kaempferia pandurata Roxb and the use thereof as an antiviral agent. The compound isolated from Kaempferia pandurata Roxb shows the ability to inhibit highly pathogenic virus, and thus is a promising candidate for an antiviral agent.Type: ApplicationFiled: February 16, 2012Publication date: December 26, 2013Applicant: KONKUK UNIVERSITY INDUSTRIAL COOPERATION CORP.Inventors: Soo Ki Kim, Jun Hyeong Lee, Hyung In moon, Sang Heui Seo, Hyun Dong Paik, Sang Buem Cho
-
Publication number: 20130316016Abstract: An antibacterial or anti-acne formulation suitable for topical or local application to human skin containing (a) either usnic acid or an usnate and (b) a metal salt selected from copper salts, bismuth salts, and mixtures thereof, wherein if the component (a) is an usnate, the components (a) and (b) are not the same compound.Type: ApplicationFiled: December 20, 2011Publication date: November 28, 2013Applicant: EVOCUTIS PLCInventors: Elizabeth Anne Eady, Daniel James Fitzgerald
-
Publication number: 20130310451Abstract: The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-?B signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed.Type: ApplicationFiled: July 18, 2011Publication date: November 21, 2013Applicant: GLACTONE PHARMA DEVELOPMENT ABInventors: Ritha Gidlöf, Martin Johansson, Olov Sterner, Eduardo Muñoz
-
Patent number: 8586112Abstract: The invention provides a process for the production of a substance or composition for the treatment, by therapy or prophylaxis, of parasitic infections, in particular malarial infections such as Plasmodium falciparum infections, of the human or animal body. The process comprises extracting the substance or composition from roots of the plant species Dicoma anomala, by an extraction using an organic solvent to obtain a liquid extract containing the substance or composition and removing the solvent from the liquid extract to leave a dried extract containing the substance or composition. The invention extends also to the use of the substance or composition in the manufacture of a medicament or preparation for such treatment of infections; to a substance or composition for use in such treatment of said infections; to compounds for use in such treatment of said infections; and to a method of treating said infections using such compounds.Type: GrantFiled: November 2, 2005Date of Patent: November 19, 2013Assignees: South African Medical Research Council, University of Cape TownInventors: Motlalepula Gilbert Matsabisa, William Ernest Campbell, Peter Ian Folb, Peter John Smith
-
Patent number: 8586575Abstract: A pharmaceutical composition comprising a drug substance consisting essentially of a pharmaceutically acceptable organic acid addition salt of an amine containing pharmaceutically active compound wherein the amine containing pharmaceutical active compound is selected from the group consisting of racemic or single isomer ritalinic acid or phenethylamine derivatives and the drug substance has a physical form selected from amorphous and polymorphic.Type: GrantFiled: April 10, 2012Date of Patent: November 19, 2013Assignee: Pisgah Laboratories, Inc.Inventors: Clifford Riley King, Stephen G. D'Ambrosio, David W. Bristol
-
Publication number: 20130302422Abstract: Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof.Type: ApplicationFiled: May 22, 2013Publication date: November 14, 2013Applicants: KT & G CORPORATION, MAZENCE INC.Inventors: Taehwan Kwak, Myung-Gyu Park, Kyoung Hoon Jung
-
Patent number: 8580847Abstract: This subject invention is directed to a method for inhibition of cancer cells, comprising administrating an effective amount of a compound of formula I (Sesquiterpene lactones, antrocin) or pharmaceutically acceptable salts thereof, together with a pharmaceutically acceptable carrier, wherein the cancer cells are selected from colorectal cancer cells, liver cancer cells, lung cancer cells or breast cancer cells.Type: GrantFiled: December 27, 2011Date of Patent: November 12, 2013Assignee: Chaoyang University of TechnologyInventors: Yew-Min Tzeng, Tien-Shen Yang, Chi-Tai Yeh Yeh
-
Publication number: 20130289105Abstract: Compositions and methods are provided for preventing or attenuating cancer progression or blocking metastasis in prostate cancer and other cancers (e.g., ovarian carcinoma, endometrial cancer, renal cell carcinoma) that are characterized by overexpression of the type II cell surface serine protease hepsin, based on the discovery of multiple disclosed compounds having activity as specific hepsin inhibitors.Type: ApplicationFiled: April 30, 2013Publication date: October 31, 2013Inventors: Valeri I. Vasioukhin, John R. Chevillet
-
Publication number: 20130261176Abstract: This invention relates to a method of detecting mechanosensing responses in bone. More specifically, the present invention provides a method to detect the expression levels of genes in mechanosensing complex to predict impaired mechanosensing response. Further, the present invention disclosed a therapeutic method for preventing bone loss and defective in bone formation by modulating the activity of the mechanosensing complex.Type: ApplicationFiled: March 14, 2013Publication date: October 3, 2013Inventors: LEIGH DARRYL QUARLES, ZHOUSHENG XIAO
-
Patent number: 8546446Abstract: Disclosed are isosorbide derivatives according to the following general formula wherein R represent a hydrogen atom, or an alkyl group with 6 to 22 C-atoms, or an acyl group, or a group X—SO3M, and M stands for a cation, a hydrogen atom or an alkali metal atom or an ammonium or an alkylammonium ion, and X represents an alkoxylated derivative (AO)n wherein AO represents a group C2H4O, or C3H6O, or any mixtures thereof, and the index n is zero or 1 to 20, and p represents a number between 1 and 10, preferably between 1 and 4, and the use thereof to prepare cleansers, detergents, personal care compositions, or cosmetic compositions.Type: GrantFiled: June 18, 2010Date of Patent: October 1, 2013Assignee: Cognis IP Management GmbHInventors: Ansgar Behler, Catherine Breffa, Hans-Christian Raths, Thorsten Löhl
-
Publication number: 20130253049Abstract: One embodiment relates to a method of treating pulmonary hypertension based upon co-administering to a subject in need thereof a pharmaceutically effective amount of an oral therapeutic agent for treating pulmonary hypertension and a pharmaceutically effective amount of an inhaled therapeutic agent for treating pulmonary hypertension. The benefit of the co-administration of these agents is to eliminate or reduce one or more side effects associated with mono-therapy of either agent, as well as one or more side effects associated with other administration routes such as subcutaneous or intravenous administration.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: United Therapeutics CorporationInventors: Martine A. Rothblatt, Lewis J. Rubin
-
Publication number: 20130252964Abstract: The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.Type: ApplicationFiled: January 18, 2013Publication date: September 26, 2013Applicant: PolyMedix, Inc.Inventors: Richard W. Scott, Katie Freeman, Haizhong Tang, Gill Diamond
-
Publication number: 20130245111Abstract: Provided is a pharmaceutical composition for the treatment and prevention of obesity, diabetes, metabolic syndromes, degenerative diseases and mitochondrial dysfunction-related diseases, comprising: a therapeutically effective amount of a compound represented by Formula I below, or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. wherein R1 through R8 and n are as defined in this disclosure.Type: ApplicationFiled: April 25, 2013Publication date: September 19, 2013Applicants: KT & G CO., LTD., MD BIOALPHA CO., LTD.Inventors: Sang-Ku YOO, Myunggyu PARK, In Geun JO, Taehwan KWAK
-
Publication number: 20130237560Abstract: A method of inhibiting excitotoxicity by indirectly activating ?4?2 nicotinic acetylcholine receptors (nAChRs) which indirectly activate synaptic AMPA and NMDA receptors is disclosed. Inhibitors of ?7 nACHRs, such as macrocyclic diterpenoids, more specifically cembranoids or methyllycaconitine (MLA), indirectly activate ?4?2 nAChRs and can be used to treat neurodegenerative diseases, including, but not limited to, Alzheimer's Disease, Parkinson Disease, AIDS related dementia and the delayed effects of stroke. They can also be used to treat diseases associated with neuronal impairment, including, but not limited to glaucoma caused by optical nerve damage, delayed effects of epilepsy; and multiple sclerosis.Type: ApplicationFiled: March 15, 2013Publication date: September 12, 2013Inventors: Peter Andrew Ferchmin, Vesna Ana Eterovic De Ferchmin, Hector Manuel Maldonado
-
Publication number: 20130225674Abstract: The invention relates to a pharmaceutical product comprising a dibenzofuranone derivative as the active ingredient. The invention further relates to the use of dibenzofuranone derivatives to inhibit kinases, in particular serine/threonine kinases, to the use of dibenzofuranone derivatives for producing drugs and/or medicinal products for treatment, and to the use of dibenzofuranone derivatives as a diagnostic product for analyzing the role of protein kinases, in particular serine/threonine kinases, in particular protein kinase CK2 in cellular processes, the pathogenesis of diseases, ontogenesis and/or other developmental biological phenomena or relationships.Type: ApplicationFiled: June 22, 2011Publication date: August 29, 2013Inventors: Joachim Jose, Claudia Götz, Andreas Gratz, Uwe Kuckländer
-
Patent number: 8513227Abstract: Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and/or endotoxic shock. Additionally provided are methods of attenuating NO release from a mammalian cell. Also provided are methods of attenuating NO production in a mammal at risk for, or having, a disorder mediated by excessive NO production.Type: GrantFiled: January 12, 2007Date of Patent: August 20, 2013Assignee: The Feinstein Institute for Medical ResearchInventors: Haichao Wang, Dazhi Chen, Andrew E. Sama
-
Publication number: 20130209534Abstract: A substrate of polymeric material for wound care contains at least one oleous antimicrobial and/or helping tissue regeneration substance that is selected from Hyperforin, Adhyperforin, 1-3 Diapigenin, 11-8 Diapigenin, Rutin, Quercetin, Hypericin, Azadirachtin ?-?, Nimbin, Nimbidin, Salanin, Gallic Acid, Gedunin and combinations thereof.Type: ApplicationFiled: June 4, 2012Publication date: August 15, 2013Applicant: MOSES S.R.L.Inventors: Chiara GUALANDI, Maria Letizia FOCARETE, Andrea ZUCCHELLI, Maria Letizia IABICHELLA
-
Patent number: 8507547Abstract: Disclosed is a composition which is safe for a human body and an animal, can be ingested continuously on a daily basis, has an anti-fatigue activity, and is effective for the prevention or treatment of a disease or condition associated with fatigue. Specifically disclosed is an anti-fatigue agent comprising andrographolide optionally together with an ?-lipoic acid as an active ingredient(s). Also disclosed is a novel oral composition comprising andrographolide and an ?-lipoic acid. The anti-fatigue agent and the oral composition are useful for the prevention or treatment of chronic fatigue syndrome, overfatigue, physical fatigue, mental fatigue and organ fatigue.Type: GrantFiled: May 30, 2008Date of Patent: August 13, 2013Assignee: Suntory Holdings LimitedInventors: Sumio Asami, Kayo Saito, Akifumi Maeda, Norifumi Tateishi
-
Patent number: 8507552Abstract: The invention provides compounds of formula (I): or a salt thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods using the compounds of formula I.Type: GrantFiled: May 7, 2010Date of Patent: August 13, 2013Assignee: Regents of the University of MinnesotaInventors: Ingrid Gunda Georg, Satish Prakash Patil, Ashok K. Saluja, Rohit Chugh, Selwyn M. Vickers
-
Publication number: 20130197075Abstract: A method of treating acquired perforating dermatosis. The method has the step of applying an amount of cantharidin to an area of skin in need of treatment thereof.Type: ApplicationFiled: July 27, 2012Publication date: August 1, 2013Inventor: Jacob LEVITT
-
Publication number: 20130189342Abstract: The present invention comprises compositions, methods and kits for delivering drugs. The invention provides an implantable device for delivery of a pharmaceutical substance to a patient, comprising a core comprising a core polymeric material optionally containing a core pharmaceutical substance, surrounded by a first layer comprising a first-layer pharmaceutical substance and a first-layer polymeric material, optionally surrounded by one or more additional layers comprising an additional pharmaceutical substance and an additional polymeric material, where the core, first, and optional additional polymeric materials may be the same or different, and where the optional core pharmaceutical substance, first-layer pharmaceutical substance, and optional additional pharmaceutical substances are the same or different. Implantation of the device allows a controlled release of drug for an extended period of time. The device may be implanted subcutaneously in an individual in need of continuous treatment with a drug.Type: ApplicationFiled: March 16, 2011Publication date: July 25, 2013Applicant: TITAN PHARMACEUTICALS, INC.Inventors: Rajesh A. Patel, Sunil R. Bhonsle
-
Publication number: 20130189380Abstract: The invention discloses herbal ingredients derived from Sphaeranthus indicus standardized to at least one frullanolide/eudesmanoid sesquiterpene compound and their compositions as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal. The invention further includes the use of ingredients and compositions for food ingredient formulations such as dietary supplement, food ingredient, beverage, snack or energy drink containing the above said herbal ingredient(s) for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal.Type: ApplicationFiled: March 11, 2013Publication date: July 25, 2013Applicant: LAILA NUTRACEUTICALSInventor: Laila Nutraceuticals
-
Publication number: 20130183275Abstract: Provided are a composition for stimulating differentiation of MSCs into osteoblasts, which includes cryptotanshinone, and an osteogenesis stimulator including cryptotanshinone and MSCs. When the cryptotanshinone is treated to the MSCs, the differentiation into osteoblasts is stimulated, and thus osteogenesis of a patient may be stimulated by directly transplanting the differentiation-induced MSCs to the patient. Accordingly, the composition or osteogenesis stimulator may be used to treat patients having disability requiring stimulation of osteogenesis such as osteoporosis, bone fracture, bone grafting including alveolar bone grafting for implant placement, or other bone defects.Type: ApplicationFiled: October 4, 2011Publication date: July 18, 2013Applicant: CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATIONInventors: Jin Hee Shin, Kyung Soo Kim, Il Kyu Lee
-
Publication number: 20130158082Abstract: The disclosure relates to methods of managing blood sugar levels and compositions related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diabetes, insulin resistance, or hyperglycemia comprising administering to a subject diagnosed with, at risk of or exhibiting symptoms of diabetes, insulin resistance, or hyperglycemia a pharmaceutical composition comprising a compound comprising formula I.Type: ApplicationFiled: September 27, 2011Publication date: June 20, 2013Applicant: EMORY UNIVERSITYInventor: Keqiang Ye
-
Publication number: 20130158094Abstract: Tricylic ether carbamates that inhibit HIV proteolytic enzymes and processes for preparing the compounds are describes. Methods of using the disclosed compounds for treating patients infected with HIV are also described.Type: ApplicationFiled: September 2, 2011Publication date: June 20, 2013Applicant: PURDUE RESEARCH FOUNDATIONInventors: Arun K. Ghosh, Chun-Xiao Xu, Hiroaki Mitsuya, Garth Parham
-
Publication number: 20130150437Abstract: The present invention discloses novel naphtho[2,3-b]furan-4,9-diones and naphtho[2,3-b]thiophene-4,9-diones and methods of making and using the same. The present invention also discloses pharmaceutical compositions comprising novel naphtho[2,3-b]furan-4,9-dione or naphtho[2,3-b]thiophene-4,9-diones for the treatment of various indications including proliferative diseases.Type: ApplicationFiled: August 24, 2010Publication date: June 13, 2013Applicant: Zhoushan HaiZhongZhou Xinsheng Pharmaceuticals Co., Ltd.Inventors: Zhiwei Jiang, Aijin Wang, Xian Li, Qingrong Li, Hongwei Hu, Jiali Xu, Yuesong Hu, Yan Ye
-
Publication number: 20130143910Abstract: A method and composition for treating cancer cells that targets fructose-1,6-biphosphataseenzymes (FBPs, type 1 and type 2) and/or their respective pathways. In one embodiment, inhibitors of FBPs or FBPs pathways are administered to a patient to treat brain cancer metastasis. In another embodiment, the present invention is particularly well suited for treating cancer cells that generally survive under glucose-independent conditions, or any other condition where cancer cells produce glucose via FBPs mediated pathways.Type: ApplicationFiled: November 14, 2012Publication date: June 6, 2013Inventor: Zhang Weihua
-
Patent number: 8455496Abstract: The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase.Type: GrantFiled: March 10, 2010Date of Patent: June 4, 2013Assignee: Pfizer Inc.Inventors: Jeffrey Allen Pfefferkorn, Anthony Lai Ling
-
Publication number: 20130136809Abstract: The invention discloses biologically active ingredient(s) selected from 7-hydroxyfrullanolide, its analogs, the ex-tract(s) and fraction(s) standardized to 7-hydroxyfrullanolide or its analogs or both or mixtures thereof or their composition(s) for the prevention, control and treatment of one or more obesity, overweight, metabolic syndrome, diabetes and other metabolic disorders or for producing lean body mass in a warm blooded animal in need thereof.Type: ApplicationFiled: January 28, 2013Publication date: May 30, 2013Applicant: LAILA NUTRACEUTICALSInventor: LAILA NUTRACEUTICALS
-
Patent number: 8450365Abstract: The present invention relates to methods for the synthesis of galanthamine, morphine, intermediates, salts and derivatives thereof. In preferred embodiments, the invention relates to methods for improving the efficiency and overall yield of said morphine, morphine related derivatives and intermediates thereof. In further embodiments, the invention relates to methods for improving the efficiency and overall yield of galanthamine and intermediates thereof.Type: GrantFiled: May 12, 2010Date of Patent: May 28, 2013Assignee: Board of Regents, The University of Texas SystemInventors: Philip D. Magnus, Ben Fauber, Neeraj Sane
-
Patent number: 8445532Abstract: Phthalide derivatives and the use of which to manufacture the sensitizer or reverser of the antineoplastic agent are described. The phthalide derivatives can enhance the sensitivity of drug-resistance tumor cells against chemotherapy and decrease the drug-resistance of tumor cells 5-30 folder and enhance notably several chemotherapy agents-induced apoptosis of tumor cells.Type: GrantFiled: September 30, 2005Date of Patent: May 21, 2013Inventors: Fei Chen, Tao Wang
-
Publication number: 20130123352Abstract: The present invention relates to a method for the treatment or prophylaxis of a disease associated with hyperproliferative cellular division, comprising administering to a subject in need thereof a therapeutically effective dosage of the pharmaceutical composition comprising xanthanodien, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.Type: ApplicationFiled: July 6, 2011Publication date: May 16, 2013Inventor: Caroline Van Haaften
-
Publication number: 20130123266Abstract: A benzene sulphonamide compound of formula I or one of its addition salts with pharmaceutically acceptable acids, for its use in a method for treating a pathology linked to an excessive effect of TNF-alpha and for its use in a method for treating the human or animal body as a direct inhibitor of TNF-alpha.Type: ApplicationFiled: July 19, 2011Publication date: May 16, 2013Applicant: VAX-CONSULTINGInventors: Jean-François Zagury, Matthieu Montes, Hadley Mouhsine, Hélène Guillemain
-
Publication number: 20130109749Abstract: The present invention provides a compound of formula (I)Type: ApplicationFiled: April 14, 2011Publication date: May 2, 2013Applicants: NANKAI UNIVERSITY, ACCENDATECHInventors: Yue Chen, Quan Zhang, Yaxin Lu, Jiadai Zhai, Yahui Ding, Jing Long, Hongxia Fan, Haoliang Zhang, Miao Wang, Weiwei Ma
-
Patent number: 8426461Abstract: The present invention provides a preparation with improved disintegration property, a preparation showing improved bioavailability of a medicament, production methods thereof and the like. A rapidly disintegrating preparation comprising granules comprising a medicament coated with a coating layer containing sugar or sugar alcohol; and a disintegrant. A production method of a rapidly disintegrating preparation including a step of producing granules comprising a medicament, a step of forming a coating layer containing sugar or sugar alcohol on the obtained granules and a step of mixing the coated granules with a disintegrant and molding the mixture.Type: GrantFiled: June 8, 2012Date of Patent: April 23, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Yutaka Tanoue, Tetsuya Matsuura, Yutaka Yamagata, Naoki Nagahara
-
Publication number: 20130079397Abstract: An industrial process for production of high-purity optically active amine derivatives in high yield while inhibiting the formation of by-products, which comprises subjecting (E)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-ylidene)ethylamine to asymmetric reduction, catalytically reducing the obtained product at a reaction temperature of 40 to 100° C. and a pH of 3 to 9, subjecting the obtained (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethylamine to propionylation, and then crystallizing the reaction mixture.Type: ApplicationFiled: August 29, 2012Publication date: March 28, 2013Applicant: Takeda Pharmaceutical Company LimitedInventors: Shinichi Urayama, Eigo Mutou, Atsushi Inagaki, Takashi Okada, Shigeharu Sugisaki
-
Patent number: 8399507Abstract: Tricyclic compounds containing a cyclopropanecarboxylic acid fused to a bicyclic ring, including pharmaceutically acceptable salts, are agonists of G-protein coupled receptor 40 (GPR40) and are useful as therapeutic compounds, particularly in the treatment of Type 2 diabetes, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.Type: GrantFiled: October 27, 2008Date of Patent: March 19, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Gui-Bai Liang, Xibin Liao, Weiguo Liu, Paul E. Finke, Dooseop Kim, Lihu Yang, Songnian Lin
-
Publication number: 20130064892Abstract: A method of making a pharmaceutical tablet comprises (a) combining (i) an aqueous networked cellulose gel with (ii) filler and (iii) an active agent to form a mixture thereof; (b) casting the mixture to form a wet tablet; (c) drying the wet tablet to form a dry pharmaceutical tablet; and then (d) optionally coating the tablet (e.g., with an enteric coating). Pharmaceutical tablets produced by such methods are also described.Type: ApplicationFiled: September 8, 2011Publication date: March 14, 2013Inventors: Raed Hashaikeh, Hatem M.N. Abushammala